Additional evidence of the dose-dependent PD-1 upregulation on CD4 and CD8 T-cells as well as PD-L1 upregulation on tumor cells and T-cells upon CEA-TCB treatment was obtained from in vitro experiments (Figures 4A–F; Supplementary Figure 6). The gene discussed is CEACAM5; the disease is neoplasm.